Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
9 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06529523 | Tislelizumab in People With Colorectal Cancer | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT04771871 | MicroRNA Profiles in Triple Negative Breast Cancer(TARMAC) | recruiting | Phase 2 | 42 | University College Hospital, IbadanOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06291064 | Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer(TARMAC) | recruiting | Phase 2 | 85 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06348134 | Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery | recruiting | Phase 2 | 74 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03879577 | Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer | active not recruiting | Phase 2 | 53 | University of ChicagoOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07022743 | Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy | active not recruiting | Phase 2 | 75 | Obafemi Awolowo UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03058939 | Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT01936064 | The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 60 | Lagos State UniversityOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT00347438 | Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer | terminated | Phase 2 | 18 | University of ChicagoOTHER | 2 | Dec 14, 2015 | clinicaltrials |
Data updated 12 days agoSource updated unknownsource: clinicaltrials